Our pipeline is focused on the development of microRNA-based oligonucleotide therapeutics (ONTs) to treat human obesity, type 2 diabetes mellitus, and NAFLD/NASH, pathologies characterized by fat accumulation, lipotoxicity, insulin resistance and chronic inflammation.
